Correlation Between Inozyme Pharma and Eyenovia
Can any of the company-specific risk be diversified away by investing in both Inozyme Pharma and Eyenovia at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inozyme Pharma and Eyenovia into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Inozyme Pharma and Eyenovia, you can compare the effects of market volatilities on Inozyme Pharma and Eyenovia and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inozyme Pharma with a short position of Eyenovia. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inozyme Pharma and Eyenovia.
Diversification Opportunities for Inozyme Pharma and Eyenovia
0.8 | Correlation Coefficient |
Very poor diversification
The 3 months correlation between Inozyme and Eyenovia is 0.8. Overlapping area represents the amount of risk that can be diversified away by holding Inozyme Pharma and Eyenovia in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Eyenovia and Inozyme Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inozyme Pharma are associated (or correlated) with Eyenovia. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Eyenovia has no effect on the direction of Inozyme Pharma i.e., Inozyme Pharma and Eyenovia go up and down completely randomly.
Pair Corralation between Inozyme Pharma and Eyenovia
Given the investment horizon of 90 days Inozyme Pharma is expected to generate 0.2 times more return on investment than Eyenovia. However, Inozyme Pharma is 4.89 times less risky than Eyenovia. It trades about -0.73 of its potential returns per unit of risk. Eyenovia is currently generating about -0.31 per unit of risk. If you would invest 478.00 in Inozyme Pharma on August 28, 2024 and sell it today you would lose (214.00) from holding Inozyme Pharma or give up 44.77% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Strong |
| Accuracy | 100.0% |
| Values | Daily Returns |
Inozyme Pharma vs. Eyenovia
Performance |
| Timeline |
| Inozyme Pharma |
| Eyenovia |
Inozyme Pharma and Eyenovia Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Inozyme Pharma and Eyenovia
The main advantage of trading using opposite Inozyme Pharma and Eyenovia positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inozyme Pharma position performs unexpectedly, Eyenovia can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eyenovia will offset losses from the drop in Eyenovia's long position.| Inozyme Pharma vs. Eliem Therapeutics | Inozyme Pharma vs. HCW Biologics | Inozyme Pharma vs. Scpharmaceuticals | Inozyme Pharma vs. Milestone Pharmaceuticals |
| Eyenovia vs. Reviva Pharmaceuticals Holdings | Eyenovia vs. Cidara Therapeutics | Eyenovia vs. Fortress Biotech | Eyenovia vs. Reviva Pharmaceuticals Holdings |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Other Complementary Tools
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |